Coya Therapeutics, Total Cash From Operating Activities Over Time
| COYA Stock | 6.38 0.12 1.85% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Coya Therapeutics, Performance and Coya Therapeutics, Correlation. Coya |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coya Therapeutics,. If investors know Coya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Coya Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Revenue Per Share 0.687 | Return On Assets (0.29) | Return On Equity (0.51) |
The market value of Coya Therapeutics, Common is measured differently than its book value, which is the value of Coya that is recorded on the company's balance sheet. Investors also form their own opinion of Coya Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Coya Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coya Therapeutics,'s market value can be influenced by many factors that don't directly affect Coya Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Coya Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Coya Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Coya Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Cash From Operating Activities Analysis
Compare Coya Therapeutics, Common and related stocks such as Cue Biopharma, Lantern Pharma, and Fennec Pharmaceuticals Total Cash From Operating Activities Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CUE | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (6 M) | (12.2 M) | (26.4 M) | (30.8 M) | (32.5 M) | (38.8 M) | (41.8 M) | (40 M) | (42 M) |
| LTRN | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (2.1 M) | (5.7 M) | (10.6 M) | (12.8 M) | (14.3 M) | (13.6 M) |
| FENC | (1.2 M) | (3.2 M) | (3 M) | (2.2 M) | (1.7 M) | (1.9 M) | (2.1 M) | (3.6 M) | (7.8 M) | (9.1 M) | (15.6 M) | (14.2 M) | (18.1 M) | (17.1 M) | (16.3 M) |
| ABOS | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (7.5 M) | (18 M) | (35.2 M) | (43.1 M) | (40.9 M) |
| INZY | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (18.8 M) | (36 M) | (48.2 M) | (57.8 M) | (70.7 M) | (67.1 M) |
| TERN | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (66.2 M) | (29.8 M) | (41.8 M) | (49.1 M) | (67.4 M) | (70.8 M) |
| DAWN | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (13.5 M) | (48.5 M) | (109.9 M) | (146.9 M) | (139.5 M) |
| CGTX | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.4 M) | (3.6 M) | (18.5 M) | (16 M) | (15.2 M) |
| TFFP | (359.4 K) | (359.4 K) | (359.4 K) | (359.4 K) | (359.4 K) | (359.4 K) | (359.4 K) | (187.7 K) | (2.1 M) | (11.2 M) | (16.6 M) | (29.6 M) | (27.3 M) | (16 M) | (16.8 M) |
| TCRX | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (3 M) | (48.7 M) | (66.5 M) | (61.4 M) | (64.4 M) |
| DRMA | (3.9 M) | (3.9 M) | (3.9 M) | (3.9 M) | (3.9 M) | (3.9 M) | (3.9 M) | (3.9 M) | (3.9 M) | (3.9 M) | (4 M) | (5.7 M) | (8.8 M) | (6.4 M) | (6.7 M) |
| NAMSW | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (25.2 M) | 8 M | (141.2 M) | (134.2 M) |
| CNTA | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (10.6 M) | (136.1 M) | (200.5 M) | (160.3 M) | (168.4 M) |
| STRO | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (37.1 M) | 12.7 M | (65 M) | (67.8 M) | (81.7 M) | 3.5 M | (111.6 M) | (106 M) |
| OPT | (0.03) | (7.3 M) | (5.2 M) | (4.2 M) | (5 M) | (3.7 M) | (6 M) | (19.9 M) | (11.9 M) | (5.7 M) | (61.1 M) | (98.4 M) | (179.3 M) | (161 M) | (153 M) |
| HLVX | (474 K) | (474 K) | (474 K) | (474 K) | (474 K) | (474 K) | (474 K) | (474 K) | (474 K) | (474 K) | (1.3 M) | (7.3 M) | (62 M) | (86.8 M) | (82.4 M) |
| GANX | (744.5 K) | (744.5 K) | (744.5 K) | (744.5 K) | (744.5 K) | (744.5 K) | (744.5 K) | (744.5 K) | (744.5 K) | (1.9 M) | (3.2 M) | (12.4 M) | (14.7 M) | (18.9 M) | (17.9 M) |
| INAB | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (4.8 M) | (7.1 M) | (13.5 M) | (24.1 M) | (23.3 M) | (22.2 M) |
Coya Therapeutics, Common and related stocks such as Cue Biopharma, Lantern Pharma, and Fennec Pharmaceuticals Total Cash From Operating Activities description
My Equities
My Current Equities and Potential Positions
| Coya Therapeutics, Common | COYA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Texas; U.S.A |
| Exchange | NASDAQ Exchange |
null 6.38
Check out Coya Therapeutics, Performance and Coya Therapeutics, Correlation. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Coya Therapeutics, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.